The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence

Completed · Phase 2

Conditions studied: Opioid Dependence

In brief

In this 5-year study, the investigators propose to evaluate the separate and combined effects of the FDA-approved formulation of extended release naltrexone (Vivitrol®) and employment-based reinforcement of opiate abstinence in promoting opiate abstinence and reducing risky injection behavior in recently detoxified, opioid-dependent, injection drug users.

Key facts

Study ID: NCT01556425
Run by: Johns Hopkins University
People needed: 84
Starts: 2012-05-01
Expected to finish: 2017-08-06
Last updated by the study team: 2018-03-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

meet the DSM-IV criteria for opioid dependence,
report using heroin at least 21 of the last 30 days while living in the community,
are unemployed,
are 18-65 years old,
are medically approved for naltrexone,
live in or near Baltimore, MD.

You may not qualify if…

have current DSM-IV major Axis I disorders
have current suicidal or homicidal ideation
express interest in methadone treatment
are required to use opioids for medical purposes
earned over $200 in taxable income over the previous 30 days while living in the community
have physical limitations that prevent them from using a keyboard
are pregnant or breastfeeding
have serum aminotransferase levels over three times normal
have known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or poly (lactide-co-glycolide) (PLG) or any other components of the diluents;
are participating in any other clinical study.

Where it is running

Johns Hopkins Bayview Center for Learning and Health — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.